In some patients with breast cancer, deletion of RGS16 promotes the activation of PI3K signaling pathway by growth factors and thus promotes tumor proliferation, HER2 activation, and resistance to chemotherapeutic drugs.31 This evidence concerns the gene ERBB2 and breast carcinoma.